E J Sherman
Overview
Explore the profile of E J Sherman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
92
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mirabelli C, Bragazzi Cunha J, Wotring J, Sherman E, El Saghir J, Harder J, et al.
J Gen Virol
. 2023 Jun;
104(6).
PMID: 37342971
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a newly emerged beta-coronavirus that enter cells via two routes, direct fusion at the plasma membrane or endocytosis followed by fusion with...
2.
Mirabelli C, Sherman E, Bragazzi Cunha J, Wotring J, El Saghir J, Harder J, et al.
bioRxiv
. 2022 Jun;
PMID: 35702152
SARS-CoV-2 is a newly emerged beta-coronavirus that enter cells via two routes, direct fusion at the plasma membrane or endocytosis followed by fusion with the late endosome/lysosome. While the viral...
3.
Dunn L, Fury M, Xiao H, Baxi S, Sherman E, Korte S, et al.
Ann Oncol
. 2018 Jan;
29(7):1606.
PMID: 29300804
No abstract available.
4.
Dunn L, Fury M, Xiao H, Baxi S, Sherman E, Korte S, et al.
Ann Oncol
. 2017 Sep;
28(10):2533-2538.
PMID: 28961834
Background: Activating events along the PI3K/mTOR pathway are common in head and neck squamous cell carcinomas (HNSCC), and preclinical studies suggest additive or synergistic effects when combining mTORC1 inhibitors with...
5.
Ho A, Dunn L, Sherman E, Fury M, Baxi S, Chandramohan R, et al.
Ann Oncol
. 2016 Aug;
27(10):1902-8.
PMID: 27566443
Background: Recurrent/metastatic adenoid cystic carcinoma (ACC) is an incurable disease with no standard treatments. The majority of ACCs express the oncogenic transcription factor MYB (also c-myb), often in the context...
6.
Fury M, Sherman E, Rao S, Wolden S, Smith-Marrone S, Mueller B, et al.
Ann Oncol
. 2014 Feb;
25(3):689-694.
PMID: 24496920
Background: There is a clinical need to improve the efficacy of standard cetuximab + concurrent intensity-modulated radiation therapy (IMRT) for patients with locally and/or regionally advanced HNSCC. Taxanes have radiosensitizing...
7.
Pfister D, Sherman E, Wolden S
Cancer Invest
. 2001 Apr;
19(2):217-8.
PMID: 11296625
No abstract available.
8.
Sherman E, Pfister D, Ruchlin H, Rubin D, Radzyner M, Kelleher G, et al.
Cancer
. 2001 Mar;
91(4):841-53.
PMID: 11241254
Background: There are limited data available regarding the cost of care in patients with androgen independent prostate carcinoma (AIPC), and there are no data on the impact of direct nonmedical...
9.
Sherman E, Ruchlin H, Holden J, Pfister D
Hematol Oncol Clin North Am
. 1999 Sep;
13(4):867-81.
PMID: 10494519
With the continued increase in medical expenditures and the growing awareness that resources are not limitless, there is increasing pressure to curb health care costs and to establish priorities. As...